Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GOVX B11

Drug Profile

GOVX B11

Alternative Names: GEO-D03 DNA vaccine; GeoVax Clade B DNA/MVA HIV/AIDS Vaccine; GOVX B01; GOVX-B; pGA2-JS7 + MVA/HIV62

Latest Information Update: 15 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GeoVax Labs; National Institute of Allergy and Infectious Diseases
  • Developer GeoVax Labs
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 15 Mar 2018 Phase I development is ongoing for HIV infections (GeoVax website, March 2018)
  • 12 Dec 2017 American Gene Technologies has patent protection for gamma delta T cells in USA
  • 09 Nov 2017 GeoVax plans an additional phase I trial for HIV infection in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top